

1. Record Nr.	UNINA9910786702203321
Titolo	Sustaining the drive to overcome the global impact of neglected tropical diseases : second WHO report on neglected tropical diseases
Pubbl/distr/stampa	Geneva, Switzerland : , : World Health Organization, , [2013] ©2013
ISBN	92-4-069066-2
Descrizione fisica	1 online resource (153 p.)
Disciplina	615.19
Soggetti	Tropical medicine Communicable diseases - Prevention Parasitic diseases Developing countries
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"Produced under the overall direction and supervision of Dr. Lorenzo Savioli (Director) and Dr. Denis Daumerie (Programme Manager), WHO Department of Control of Neglected Tropical Diseases"--Back of title page.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Cover; Contents; FOREWORD BY THE DIRECTOR-GENERAL OF THE WORLD HEALTH ORGANIZATION; SUMMARY; 1 THE GLOBAL PUBLIC-HEALTH AGENDA NOW EMBRACES NEGLECTED TROPICAL DISEASES; 1.1 Recent developments in prevention and control; 1.2 The roadmap and the London declaration; 1.3 Opportunities for public-health programmes; 1.4 Costs of expanding activities; 1.5 WHO and the roadmap's targets; REFERENCES; 2 REACHING THE ROADMAP'S TARGETS; 2.1 Practical definitions of eradication, elimination and control; 2.2 Obstacles and risks to achieving targets; 2.2.1 Conflicts and population displacement 2.2.2 Population growth 2.2.3 Vector control; 2.2.4 Resistance to medicines and pesticides; 2.2.5 Insufficient capacity for scaling up; 2.2.6 Expectations overtaking science; 2.2.7 Inadequate support for research; 2.2.8 Climate change; REFERENCES; 3 DISEASES; REFERENCES; WOMEN, CHILDREN AND NEGLECTED TROPICAL DISEASES; Biological consequences; Sociocultural consequences; Stigma; REFERENCES; 3.1 Dengue; Introduction; Distribution; Impact; Strategy (roadmap targets

and milestones); REFERENCES; 3.2 Rabies; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES  
3.3 Trachoma Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.4 Buruli ulcer; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.5 Endemic treponematoses; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.6 Leprosy; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.7 Chagas disease; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.8 Human African trypanosomiasis (sleeping sickness) Introduction Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.9 Leishmaniases; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.10 Taeniasis/cysticercosis; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.11 Dracunculiasis (guinea-worm disease); Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.12 Echinococcosis; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.13 Foodborne trematodiases Introduction Distribution; Strategy (roadmap targets and milestones); REFERENCES; 3.14 Lymphatic filariasis; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.15 Onchocerciasis (river blindness); Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.16 Schistosomiasis; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES; 3.17 Soil-transmitted helminthiases; Introduction; Distribution; Impact; Strategy (roadmap targets and milestones); REFERENCES

#### 4 KEY INTERVENTIONS: SITUATION REPORT

#### Sommario/riassunto

The second WHO report on neglected tropical diseases builds on the growing sense of optimism generated by the 2012 publication of the WHO Roadmap. Commitments on the part of ministries of health in endemic countries global health initiatives funding agencies and philanthropists have escalated since 2010 as have donations of medicines from pharmaceutical companies and the engagement of the scientific community. This report marks a new phase and assesses opportunities and obstacles in the control elimination and eradication of several of these diseases. Unprecedented progress over the past two years ha